Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Cash (2016 - 2025)

Historic Change in Cash for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q2 2025 value amounting to -$35.7 million.

  • KalVista Pharmaceuticals' Change in Cash fell 50843.93% to -$35.7 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$17.1 million, marking a year-over-year increase of 2987.85%. This contributed to the annual value of $100.5 million for FY2025, which is 51099.02% up from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Change in Cash of -$35.7 million as of Q2 2025, which was down 50843.93% from $9.7 million recorded in Q4 2024.
  • KalVista Pharmaceuticals' Change in Cash's 5-year high stood at $9.7 million during Q4 2024, with a 5-year trough of -$35.7 million in Q2 2025.
  • For the 3-year period, KalVista Pharmaceuticals' Change in Cash averaged around -$7.2 million, with its median value being $59000.0 (2024).
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Change in Cash soared by 10086.4% in 2024, and later plummeted by 50843.93% in 2025.
  • KalVista Pharmaceuticals' Change in Cash (Quarter) stood at $8.3 million in 2023, then grew by 17.88% to $9.7 million in 2024, then plummeted by 466.47% to -$35.7 million in 2025.
  • Its Change in Cash stands at -$35.7 million for Q2 2025, versus $9.7 million for Q4 2024 and $59000.0 for Q3 2024.